Pneumonia- VUMC eMERGE v5.1
Identify bacterial pneumonia, similar to that reported with genetic association risk in CD143 and TLR4 A229G in literature.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Medications
Post-event Pain algorithm
Pain is a personal, multidimensional experience in which genetic biomarkers has a main role in determining pain sensitivity, perception and tolerance. Pain is a major concern for surgical patients and post-operative pain management still present a major challenge both in inpatient or outpatient settings. Apart from genetic factors, there are many other variables that may affect pain perception for example, pretreated patients may require less post-surgical medications, and they may recover more quickly.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Red Blood Cell Indices
Laboratory results for ESR and RBC indices (hemoglobin, MCV, MCH, RDW… etc) should be extracted from the Laboratory databases. For Mayo, from January 1994 till October 2009, ESR and RBC test results were populated for our 3336 participants. All samples were collected on an outpatient basis. Samples collected during an inpatient hospitalization (admit date ≤ collection date ≤ discharge date) should be excluded unless this sample was the only one available for a patient.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Resistant hypertension
This algorithm describes the ongoing resistant hypertension algorithm used in eMERGE, which was a network phenotype within the eMERGE-I and eMERGE-II sites.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Rheumatoid Arthritis - Demonstration Project
Rheumatoid Arthritis phenotype algorithm for the DNA Databank demonstration project.
|
|
Record Count |
Diagnostic Codes? |
Text Keywords? |
Narrative Notes to search |
Other rules |
|
Cases |
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Rheumatology Auto-Immune characteristics
Dear,
To identify cases with auto-immune rheumatologic phenotye (for NT198) we request information about auto-antibody (whether it was tested and what the restults were) and drug information (whether it was prescribed) for each patients that is enrolled in eMERGE. We are requesting every mention of any of the expanded generic drugs.
Owner Phenotyping Groups:
Final
RxNorm RxCUI codes for Cancer Therapies
This phenotype includes RxNorm RxCUI codes for cancer therapies. These codes map to drug records in the PCORnet Common Data Model and other data sources. The phenotype was developed in 2019. Please see the associated files for additional information.
The development of this phenotype was supported by a Patient-Centered Outcomes Research Institute (PCORI) Award (No. CDRN-1306-04631) for the development of the national patient-centered clinical research network, known as PCORnet.
Owner Phenotyping Groups:
Final
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria
Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Steroid Induced Osteonecrosis
View Phenotyping Groups:
Final